Comparative Pharmacology
Head-to-head clinical analysis: ORTHO NOVUM 10 11 28 versus ORTHO TRI CYCLEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ORTHO NOVUM 10 11 28 versus ORTHO TRI CYCLEN.
ORTHO-NOVUM 10/11-28 vs ORTHO TRI-CYCLEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive; suppresses gonadotropins (FSH, LH) via negative feedback inhibition of hypothalamic-pituitary axis, preventing ovulation; increases cervical mucus viscosity, impeding sperm penetration; alters endometrial development, reducing implantation likelihood.
Combined estrogen-progestin oral contraceptive; suppresses gonadotropin release, inhibiting ovulation; increases cervical mucus viscosity and alters endometrial lining.
One tablet daily for 28 days, starting on day 1 of menstrual cycle. Each tablet contains 1 mg norethindrone and 10 mcg ethinyl estradiol for first 10 tablets, then 1 mg norethindrone and 35 mcg ethinyl estradiol for next 11 tablets, followed by 7 placebo tablets.
One tablet (norgestimate 0.180-0.215-0.250 mg/ethinyl estradiol 0.035 mg) orally once daily for 21 days, followed by 7 days of placebo or no tablets.
None Documented
None Documented
Norethindrone: 5-14 hours; Ethinyl estradiol: 8-20 hours. Steady state reached within 5 days. Clinical significance: missed doses may increase pregnancy risk due to rapid decline.
Norethindrone: ~8 hours (terminal). Ethinyl estradiol: ~12-15 hours (terminal). Clinical context: Steady-state achieved within 5-7 days; contraceptive efficacy maintained with daily dosing.
Renal (50-60% as metabolites, <10% unchanged); fecal (30-40%) with biliary elimination of conjugates.
Norethindrone: 60-80% renal (as metabolites), 20-40% fecal. Ethinyl estradiol: ~40% renal, ~60% fecal. Biliary excretion contributes to fecal elimination.
Category C
Category C
Hormonal Contraceptive
Hormonal Contraceptive